Information on HER2 status, PD-L1 expression, MSI and overall mutational burden—currently the preserve of metastatic disease algorithms—might be increasingly relevant for the incorporation of targeted therapy within treatment plans, and to help guide the response to therapy [94, 109, 110]. This evidence concerns the gene ERBB2 and metastatic neoplasm.